cIPV

BIOLOGICAL2 trials

Sponsors

Janssen Vaccines & Prevention B.V.

Conditions

Healthy

Phase 1

A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults

CompletedNCT03032588

Janssen Vaccines & Prevention B.V.Healthy

Start: 2017-10-09End: 2018-05-18Updated: 2025-02-03

Phase 2

A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule

CompletedNCT03566940

Janssen Vaccines & Prevention B.V.Healthy

Start: 2018-07-31End: 2019-10-17Updated: 2025-02-03

Related Papers

Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

Human Vaccines & Immunotherapeutics2020-11-117 citations